Cutaneous manifestations of connective tissue disease.

Abstract	There is evidence that early treatment of connective tissue in adolescence improves clinical outcomes; thus, recognition of the cutaneous manifestation of CTD is critical. This review summarizes the clinical features that are unique to children and adolescents in cutaneous (CLE) and systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), juvenile systemic scleroderma (JSS), juvenile localized scleroderma (JLS), and juvenile inflammatory arthritis (JIA).
Authors	Erin McCammack, Anita N Haggstrom
Journal	Adolescent medicine: state of the art reviews (Adolesc Med State Art Rev) Vol. 22 Issue 1 Pg. 35-53 (Apr 2011) ISSN: 1934-4287 [Print] United States
PMID	21815443 (Publication Type: Journal Article)
Chemical References	Antirheumatic Agents Glucocorticoids Immunosuppressive Agents Hydroxychloroquine
Topics	Adolescent Antirheumatic Agents (therapeutic use) Connective Tissue Diseases (drug therapy, physiopathology) Glucocorticoids (therapeutic use) Humans Hydroxychloroquine (therapeutic use) Immunosuppressive Agents (therapeutic use) Lupus Erythematosus, Cutaneous (drug therapy, physiopathology) Lupus Erythematosus, Discoid (drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!